BO1 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - BioCryst Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 7.49 EUR -2.68% Market Closed

Market Cap: €1.5B

B	BioCryst Pharmaceuticals Inc SWB:BO1	US
R	Republic Services Inc F:RPU	US
N	New York Times Co F:NYT	US
E	Ems Chemie Holding AG XMUN:EMC1	CH
	Orthocell Ltd ASX:OCC	AU

Profitability Summary

BioCryst Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

98%

Strong 3Y Average Gross Margin

98%

Gross Margin is Increasing

97% > 98%

Exceptional Operating Margin

36%

Negative 3Y Average Operating Margin

-5%

Operating Margin is Increasing

-44% > 36%

Negative Net Margin

-52%

Negative 3Y Average Net Margin

-34%

Net Margin is Increasing

-78% > -52%

Exceptional Free Cash Flow Margin

35%

Negative 3Y Average Free Cash Flow Margin

-9%

Free Cash Flow Margin is Increasing

-46% > 35%

Exceptional ROE

91%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-3%

ROIC is Increasing

-147% > 163%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.